Mid-Cap Biopharmas Flex Their Commercial Muscle
Companies like argenx, Insmed and Madrigal are executing successfully in the commercial market and attracting investor attention. Their success could pave the way for more.
Scrip - February 2, 2026

Out Of Gummy Vitamins, C&D Gets Into Growing Market Share In Toothpaste, Internationally
C&D starts 2026 with expectations to boost sales of latest acquisition, Touchland scented hand sanitizer, after halting sales of Flawless hair removal/nail care and Waterpik showerhead products and selling Spinbrush power toothbrush brand as well vitafusion and L’il Critter gummy supplement lines.
HBW Insight - February 2, 2026

BMS Confident Its New Drugs Will Grow More Than Its Old Ones Shrink
Bristol Myers Squibb execs David Elkins and Adam Lenkowsky spoke with Scrip about the company’s efforts to grow new products and advance novel drugs before Opdivo and Eliquis lose exclusivity in 2028.
Scrip - February 2, 2026

People On The Move: Appointments At Angelini, Pierre Fabre, Boots
A round-up of the latest European people moves: Angelini hires external affairs chief; Pierre Fabre appoints impact and reputation officer; Boots changes leadership at the top.
HBW Insight - February 2, 2026

New Lancet Study ‘Decisively Rejects’ Trump’s Paracetamol In Pregnancy Claims
A new Lancet meta-analysis finds no evidence that paracetamol use in pregnancy increases the risk of autism, ADHD, or intellectual disability, decisively refuting claims made by US President Donald Trump and reaffirming regulatory guidance that the drug remains safe when used as directed.
HBW Insight - February 2, 2026

At INBRAIN’s 5-Year Mark, BCI Experts Confront The Promise, Perils Of Brain-Computer Interfaces
Medtech Insight was invited to moderate a panel discussion with leading experts in neuroscience and AI during INBRAIN’s five-year anniversary in Barcelona, Spain. Panelists discussed the promises, perils in BCI development, neuroethics and outlook.
Medtech Insight - February 2, 2026

Novo Set To Make MASH Move On Madrigal In EU With Kayshild
The Danish drugmaker is getting ready to celebrate a first-in-class approval from the European Commission for semaglutide for metabolic dysfunction-associated steatohepatitis.
Scrip - February 2, 2026

Alvotech Hooks Up With Sandoz For Biosimilars In Canada, Australia And New Zealand
Sandoz and Alvotech have struck a deal that will see the firms collaborate on multiple biosimilar candidates for the Australian, Canadian and New Zealand markets across therapeutic areas including ophthalmology, immunology and gastroenterology.
Generics Bulletin - February 2, 2026

Sanofi Posts Hit And Miss Data For Venglustat? In Two Rare Disease Trials
Sanofi’s mixed data readout for venglustat lines up regulatory filings in neurological type 3 Gaucher's disease, while additional?analyses and a separate trial will guide its future in Fabry's disease.
Scrip - February 2, 2026

Pharming’s Expansion Plans For Joenja Hit By FDA Rejection
A complete response letter will delay Joenja’s US growth, which Pharming needs as its flagship product, Ruconest, faces growing competition.
Scrip - February 2, 2026

Transpire Bio Goes After GSK’s Trelegy Ellipta With First Generic Filing
Transpire Bio continues to advance its complex generics franchise, with another Paragraph IV filing for GSK’s Ellipta portfolio inhaler.
Generics Bulletin - February 2, 2026

Who’s Hired? Lupin’s Hoffman Named As New AAM Chair
The US Association for Accessible Medicines has named Lupin’s Bob Hoffman as its new chair. Meanwhile, departures have been seen at Stada and Dr Reddy’s, among other industry management changes.
Generics Bulletin - February 2, 2026

Pipeline Watch: Four Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - February 2, 2026

Strides Pharma: US-Led Global Fund Cut Hurts; Greater Focus On Ex-US Markets
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors
Scrip - February 2, 2026

Accelerated Approvals Perked Up While US FDA Excelled At Being Average In 2025
Accelerated approvals of novel products rebounded in 2025 as drug development adapted to major pathway changes enacted in the FDA Omnibus Reform Act, but pending applications suggest a potentially bigger impact outside oncology in 2026.
In Vivo - February 2, 2026

Navigating A Changing EU And US Sustainability Landscape, With Steve Ramus
HBW Insight speaks to ex-Perrigo ESG expert Steve Ramus about the state of sustainability in consumer health and where we might be heading in the near future. Part one of two.
HBW Insight - February 2, 2026

Podcast: How Senti Bio’s Programmable Cell Therapy Tackles AML’s Toxicity Problem
Senti Bio CEO Tim Lu explains how logic-gated CAR-NK therapy SENTI-202 distinguishes cancer from healthy cells in AML, achieving 50% response rates with favorable safety.
In Vivo - February 2, 2026

Sunshine Pharma Invests In XtalPi JV For AI/Robotics Drug Discovery
Sunshine Pharma plans to invest at least $14m to set up a joint venture with fellow Chinese firm XtalPi, with goals including the discovery and development of novel molecules for autoimmune disorders.
Scrip - February 2, 2026

PharmAbcine Founder Calls For Post-Delisting Protections For Korean Biotechs
PharmAbcine founder shares views on current lack of post-delisting protections for technology companies in South Korea, proposing special regulations to safeguard expertise and assets for a certain period.
Scrip - February 2, 2026

Pending US GRAS Rule Change Points Supplement Industry Toward More NDI Notifications
“FDA’s proposed GRAS rule would move GRAS closer to the NDI model in at least one key respect, which is mandatory notification,” says attorney Ashish Talati. Proposed rule isn’t expected to require removal of ingredients available through self-GRAS processes.
HBW Insight - February 2, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: AstraZeneca’s big China investment pledge; Novartis exec’s warning on early trial competitiveness; Chinese biotechs tap IPOs to fund foreign trials; Merck & Co on winning deals; and breaking down the India-EU free trade agreement.
Scrip - February 2, 2026

Sun On ‘Disciplined’ M&A Approach, Day 1 Launch Readiness For Semaglutide In India
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Scrip - February 2, 2026